NCT04974866 is a Phase 2 clinical trial of EGFR-TK Inhibitor in Carcinoma, Adenoid Cystic, sponsored by Qingdao Central Hospital.

Who is sponsoring NCT04974866?

NCT04974866 is sponsored by Qingdao Central Hospital.

What drugs are being tested in NCT04974866?

Interventions in NCT04974866: EGFR-TK Inhibitor.

What condition does NCT04974866 study?

NCT04974866 studies Carcinoma, Adenoid Cystic.

Is NCT04974866 still recruiting?

NCT04974866 is currently recruiting now. Last updated 29 March 2023.

Last reviewed 2023-03-29 · How we verify

NCT04974866

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tyrosine Kinase Inhibitors in Metastastic Adenoid Cystic Carcinoma

Recruiting now Phase 2 Last updated 29 March 2023

What this trial tests

Phase 2 trial testing EGFR-TK Inhibitor in Carcinoma, Adenoid Cystic in 20 participants. Currently enrolling.

Timeline

1 July 2021

Primary endpoint
31 July 2024

31 July 2026

Quick facts

Lead sponsor	Qingdao Central Hospital
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 July 2021
Primary completion	31 July 2024
Estimated completion	31 July 2026
Sites	1 location across China

Drugs / interventions tested

EGFR-TK Inhibitor — full drug profile →

Conditions studied

Carcinoma, Adenoid Cystic — all drugs for Carcinoma, Adenoid Cystic →

Sponsor

Qingdao Central Hospital

Who can join

Adults 18 to 90, any sex, with Carcinoma, Adenoid Cystic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There is no clinical study on epidermal growth factor receptor tyrosine kinase inhibitors has been systematically conducted in adenoid cystic carcinoma. This is a phase II study EGFR TKIs in adenoid cystic carcinoma to evaluate its efficacy in this disease.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Current landscape and future directions of therapeutic approaches for adenoid cystic carcinoma of the salivary glands (Review).
Stawarz K, Durzynska M, Gałązka A, Gorzelnik A, et al · · 2025 · cited 10× · PMID 39898287 · DOI 10.3892/ol.2025.14899
Real-world treatment patterns and survival outcomes in metastatic head and neck adenoid cystic carcinoma.
Bölek H, Kayaalp M, Şahin TK, Doğan OT, et al · · 2025 · PMID 41029524 · DOI 10.1186/s12885-025-14884-5

Verify or expand the search:

Other trials of EGFR-TK Inhibitor

Trials testing the same drug.

NCT06020066 — SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI · Phase 2 · active not recruiting
NCT03623750 — E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C · Phase 1, PHASE2 · completed
NCT03461185 — Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer · Phase 2 · unknown
NCT03258671 — IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer · NA · unknown

Other recruiting trials for Carcinoma, Adenoid Cystic

Currently open trials in the same condition.

NCT05733910 — Simultaneous Integrated Boost in Carbon Ion Radiotherapy for Head and Neck Adenoid Cystic Carcinoma · NA · recruiting

Other Qingdao Central Hospital trials

Trials by the same sponsor.

NCT07090525 — Bevacizumab Combined With Cisplatin Versus Cisplatin Monotherapy in Malignant Serous Effusions · Phase 2 · recruiting
NCT07090031 — Perioperative Treatment With TAS-102 in Combination With Oxaliplatin for Locally Advanced Rectal Cancer · Phase 2 · active not recruiting
NCT07322783 — Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification · Phase 2 · recruiting
NCT06500234 — Nutrition Impact on Immunotherapy of Cancer · Phase 3 · recruiting
NCT06514118 — Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04974866 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Qingdao Central Hospital
Last refreshed: 29 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04974866.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing